Bluejay Diagnostics, Inc. 8-K

What Happened

• Bluejay Diagnostics, Inc. (BJDX) filed an 8-K to report that its Board selected and implemented a 1-for-4 reverse stock split of its common stock. The Company filed a Certificate of Amendment with the Delaware Secretary of State on January 27, 2026; the Reverse Stock Split became effective at 12:01 a.m. ET on January 29, 2026 and the stock began trading on The Nasdaq Capital Market on a post-split basis at the open on January 29, 2026. The trading symbol remains "BJDX" and the new CUSIP is 095633608. The reverse split followed prior shareholder approval (at the June 18, 2025 meeting) authorizing a reverse split at ratios between 1-for-2 and 1-for-20, with the Board selecting 1-for-4.

Key Details

• Reverse split ratio: 1-for-4, effective Jan 29, 2026 at 12:01 a.m. ET.
• Share count: issued and outstanding shares reduced from 2,834,133 to approximately 708,533.
• Prefunded warrants: shares issuable reduced from 1,055,000 to 263,750.
• Corporate mechanics: par value and voting rights unchanged; no fractional shares issued — stockholders entitled to fractional shares will receive a cash payment in lieu (calculated using a recent average closing price, without interest). Continental Stock Transfer & Trust Company is handling book‑entry issuance and exchange instructions; brokers will notify street‑name holders. Equity awards, warrants, and plan reserves were proportionately adjusted (exercise prices and share counts).

Why It Matters

• The reverse split reduces the total number of outstanding shares and increases the per‑share amount, while keeping ownership percentages and voting rights unchanged (other than rounding/cashing out fractions). Investors should note the new CUSIP (095633608) and that BJDX continues to trade under the same ticker. Option/warrant holders and participants in equity plans will see proportional adjustments to share counts and exercise prices. Holders expecting fractional shares will receive cash in lieu, and record‑keeping will be handled via book‑entry through the transfer agent.